Industry & Policy News

[CANbridge Pharmaceuticals, Inc.] CANbridge Pharmaceuticals, Inc. announced that, based on the interim analysis recommendation of the independent data monitoring committee, it plans to continue the ongoing Phase II study of CAN008 in patients with newly diagnosed glioblastoma multiforme in China to completion.

[Bristol Myers Squibb] The decision was based on results from the Phase III CheckMate -816 trial, in which three cycles of Opdivo with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival and pathologic complete response compared to chemotherapy alone when administered before surgery.

[Genenta Science] Genenta's platform is designed to avoid systemic toxicity of interferon alpha and selectively deliver therapeutic activity within solid tumors like glioma.

[Icahn School of Medicine at Mount Sinai] Researchers in immunology and bioengineering at the Icahn School of Medicine at Mount Sinai have received $15.1 million from the National Institute of Allergy and Infectious Disease to lead a novel, five-year multi-center research program that will explore trained immunity—the innate immune system’s ability to remember infections and other insults.

[Gladstone Institutes] Dr. Magdalena Zernicka-Goetz was announced as the recipient of the 2023 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes. Zernicka-Goetz is a professor of mammalian development and stem cell biology in the Department of Physiology, Development, and Neuroscience at the University of Cambridge, as well as the Bren Professor of Biology and Biological Engineering at the California Institute of Technology.

[Hutch News] Fred Hutchinson Cancer Center pancreatic cancer researcher Sita Kugel, PhD, has received an inaugural Translational Research Award from the V Foundation for Cancer Research.